• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ:THTX)

3.390 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
December 09, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
December 04, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Announces Resumed Production of EGRIFTA SV®
December 03, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Examining the Future: Theratechnologies's Earnings Outlook ↗
October 09, 2024
 
Via Benzinga
News headline image
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
December 02, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
November 26, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
October 17, 2024
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF 
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
October 17, 2024
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens 
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
October 10, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
October 09, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
September 26, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays ↗
September 19, 2024
Theratechnologies anticipates a temporary supply disruption of Egrifta SV in 2025 due to an FDA-linked manufacturer shutdown, but the company is working to minimize the impact while adjusting revenue... 
Via Benzinga
News headline image
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
September 17, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Present at Upcoming Investor Conferences in September
September 09, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024 ↗
July 10, 2024
THTX stock results show that Theratechnologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars ↗
July 10, 2024
Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The... 
Via Benzinga
News headline image
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
July 10, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
June 26, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 23, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Reports on its Annual Meeting of Shareholders
May 09, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
April 15, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024 ↗
April 10, 2024
THTX stock results show that Theratechnologies beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
April 10, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Earnings Scheduled For April 10, 2024 ↗
April 10, 2024
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion. 
Via Benzinga
News headline image
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies Appoints Elina Tea to its Board of Directors
April 05, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
April 03, 2024
From Theratechnologies
Via GlobeNewswire
News headline image
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
March 28, 2024
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap